About Melt Pharmaceuticals
Melt Pharmaceuticals is a private company based in Brentwood, Tennessee, incorporated in 2019 in Delaware. It has reported $53,727,450 raised in two offerings on Form D since February 2019.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 28, 2023 | Aug 11, 2023amended Apr 8, 2024 | $42,292,450of $47.7M target | 309 | $136K | EquityRule 506(b) | Form D/A ↗8 earlier filings |
| Jan 30, 2019 | Feb 13, 2019amended Apr 5, 2019 | $11,435,000of $25.7M target | 165 | $69,303 | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $53,727,450 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Melt Pharmaceuticals's Form D filed Apr 8, 2024.
LD
Larry Dillaha
Executive officer and director
BO
Brad Osborne
Chief Financial Officer
Earlier filings also listed Mark Baum (director, last listed Apr 2019), John Berdahl (director, last listed Apr 2019), Gregory Madison (president & ceo, director, last listed Apr 2019) and Andrew Boll (director, last listed Apr 2019).
Sources
- SECMelt Pharmaceuticals, Inc. Form D/A, filed Mar 11, 2024
- SECMelt Pharmaceuticals, Inc. Form D/A, filed Feb 12, 2024
- SECMelt Pharmaceuticals, Inc. Form D/A, filed Jan 9, 2024
- SECMelt Pharmaceuticals, Inc. Form D/A, filed Dec 11, 2023
- SECMelt Pharmaceuticals, Inc. Form D/A, filed Nov 13, 2023
- SECMelt Pharmaceuticals, Inc. Form D/A, filed Oct 13, 2023
- SECMelt Pharmaceuticals, Inc. Form D/A, filed Sep 12, 2023
- SECMelt Pharmaceuticals, Inc. Form D, filed Aug 11, 2023
- SECMelt Pharmaceuticals, Inc. Form D, filed Feb 13, 2019
- SECMelt Pharmaceuticals, Inc. filing history